AG˹ٷ

STOCK TITAN

[FWP] Morgan Stanley Free Writing Prospectus

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
FWP
Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. (TMO) filed a Form 4 on July 1, 2025 disclosing that director Jennifer M. Johnson was credited with 76.54 phantom stock units on June 28, 2025 under the company’s Deferred Compensation Plan for Directors. The units, valued at $408.28 each, convert to common stock on a 1-for-1 basis when the director leaves the board or upon a change of control. After the credit, Johnson holds 474.05 stock-equivalent units, all recorded as direct ownership.

The transaction represents routine deferral of quarterly board retainer fees rather than an open-market purchase or sale. With an estimated market value of roughly $31 thousand, the filing is financially immaterial relative to Thermo Fisher’s multi-billion-dollar market capitalization. No options were exercised, no common shares were sold, and the company’s share count and cash position remain unchanged. The filing nevertheless reinforces incentive alignment by tying a portion of Johnson’s compensation to future shareholder returns.

Thermo Fisher Scientific Inc. (TMO) ha presentato un Modulo 4 il 1° luglio 2025, comunicando che la direttrice Jennifer M. Johnson ha ricevuto 76,54 unità di azioni fantasma il 28 giugno 2025 nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le unità, valutate 408,28 $ ciascuna, si convertono in azioni ordinarie con un rapporto di 1 a 1 quando la direttrice lascia il consiglio o in caso di cambio di controllo. Dopo l'accredito, Johnson detiene 474,05 unità equivalenti ad azioni, tutte registrate come proprietà diretta.

La transazione rappresenta un differimento ordinario delle commissioni trimestrali del consiglio, piuttosto che un acquisto o una vendita sul mercato aperto. Con un valore di mercato stimato di circa 31 mila $, la comunicazione è finanziariamente irrilevante rispetto alla capitalizzazione di mercato multimiliardaria di Thermo Fisher. Non sono state esercitate opzioni, non sono state vendute azioni ordinarie e il numero di azioni e la posizione di cassa della società rimangono invariati. Tuttavia, la comunicazione rafforza l'allineamento degli incentivi legando una parte della retribuzione di Johnson ai futuri rendimenti per gli azionisti.

Thermo Fisher Scientific Inc. (TMO) presentó un Formulario 4 el 1 de julio de 2025, revelando que la directora Jennifer M. Johnson recibió 76,54 unidades ficticias de acciones el 28 de junio de 2025 bajo el Plan de Compensación Diferida para Directores de la compañía. Las unidades, valoradas en $408,28 cada una, se convierten en acciones ordinarias en una proporción de 1 a 1 cuando la directora deja la junta o en caso de un cambio de control. Tras el crédito, Johnson posee 474,05 unidades equivalentes a acciones, todas registradas como propiedad directa.

La transacción representa un diferimiento rutinario de las tarifas trimestrales de retención del consejo, en lugar de una compra o venta en el mercado abierto. Con un valor de mercado estimado de aproximadamente $31 mil, la presentación es financieramente insignificante en relación con la capitalización de mercado multimillonaria de Thermo Fisher. No se ejercieron opciones, no se vendieron acciones ordinarias y el recuento de acciones y la posición de efectivo de la empresa permanecen sin cambios. No obstante, la presentación refuerza la alineación de incentivos al vincular una parte de la compensación de Johnson con los futuros rendimientos para los accionistas.

Thermo Fisher Scientific Inc. (TMO)� 2025� 7� 1� Form 4� 제출하여 이사 Jennifer M. Johnson� 2025� 6� 28� 회사� 이사 연기 보상 계획� 따라 76.54 팬텀 스톡 유닛� 부여받았음� 공개했습니다. � 유닛은 $408.28� 가치가 있으�, 이사가 이사회에� 물러나거� 지배권 변� � 1대1 비율� 보통주로 전환됩니�. 해당 부� � Johnson은 � 474.05 주식 등가 유닛� 보유하고 있으�, 모두 직접 소유� 기록되어 있습니다.

이번 거래� 공개 시장에서� 매매가 아닌 분기� 이사� 보수� 일상적인 이연� 나타냅니�. � $31,000� 추정 시장 가치를 가� � 신고� Thermo Fisher� 수십� 달러 규모 시가총액� 비해 재무적으� 미미� 수준입니�. 옵션 행사� 보통� 매각은 없었으며, 회사� 주식 수와 현금 보유액도 변동이 없습니다. 그럼에도 불구하고 이번 신고� Johnson� 보상� 일부� 미래 주주 수익� 연계하여 인센티브 정렬� 강화합니�.

Thermo Fisher Scientific Inc. (TMO) a déposé un formulaire 4 le 1er juillet 2025, révélant que la directrice Jennifer M. Johnson a été créditée de 76,54 unités d'actions fictives le 28 juin 2025 dans le cadre du Plan de Rémunération Différée pour les Administrateurs de la société. Ces unités, évaluées à 408,28 $ chacune, se convertissent en actions ordinaires à raison de 1 pour 1 lorsque la directrice quitte le conseil d'administration ou en cas de changement de contrôle. Après ce crédit, Johnson détient 474,05 unités équivalentes en actions, toutes enregistrées en propriété directe.

Cette opération représente un report habituel des honoraires trimestriels du conseil d'administration, plutôt qu'un achat ou une vente sur le marché ouvert. Avec une valeur marchande estimée à environ 31 000 $, cette déclaration est financièrement insignifiante par rapport à la capitalisation boursière de plusieurs milliards de dollars de Thermo Fisher. Aucune option n'a été exercée, aucune action ordinaire vendue, et le nombre d'actions ainsi que la trésorerie de la société restent inchangés. Néanmoins, cette déclaration renforce l'alignement des incitations en liant une partie de la rémunération de Johnson aux futurs rendements pour les actionnaires.

Thermo Fisher Scientific Inc. (TMO) reichte am 1. Juli 2025 ein Formular 4 ein und gab bekannt, dass die Direktorin Jennifer M. Johnson am 28. Juni 2025 im Rahmen des Deferred Compensation Plans für Direktoren mit 76,54 Phantom-Aktieneinheiten gutgeschrieben wurde. Die Einheiten, die jeweils mit 408,28 $ bewertet sind, werden im Verhältnis 1:1 in Stammaktien umgewandelt, wenn die Direktorin den Vorstand verlässt oder es zu einem Kontrollwechsel kommt. Nach der Gutschrift hält Johnson 474,05 aktienäquivalente Einheiten, die alle als Direktbesitz verbucht sind.

Die Transaktion stellt eine routinemäßige Aufschiebung der vierteljährlichen Vorstandsvergütung dar und ist kein Kauf oder Verkauf am offenen Markt. Mit einem geschätzten Marktwert von etwa 31.000 $ ist die Meldung finanziell unbedeutend im Vergleich zur milliardenschweren Marktkapitalisierung von Thermo Fisher. Es wurden keine Optionen ausgeübt, keine Stammaktien verkauft, und die Aktienanzahl sowie die Barposition des Unternehmens bleiben unverändert. Dennoch stärkt die Meldung die Anreizkompatibilität, indem ein Teil von Johnsons Vergütung an zukünftige Aktionärsrenditen gekoppelt wird.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine deferred-comp acquisition; negligible size, neutral impact.

The Form 4 records quarterly board-fee deferral into 76.54 phantom units, lifting the director’s stake to 474.05 units. Because phantom stock is settled only after service ends, there is no immediate liquidity event or cash flow. The $31k market value is immaterial to both the insider and TMO’s capital structure. From a governance standpoint, continued equity linkage is positive for alignment but not large enough to influence sentiment or valuation. I assign a neutral impact rating.

TL;DR: Insignificant position increase; no trading signal.

Johnson’s phantom stock credit under the director plan is administrative, not opportunistic buying. Volume (76.54 units) is de minimis versus TMO’s average daily volume and implies no informational edge. The filing does not alter supply-demand dynamics or forward fundamentals; therefore, I view the market impact as non-existent and maintain a neutral stance on the shares.

Thermo Fisher Scientific Inc. (TMO) ha presentato un Modulo 4 il 1° luglio 2025, comunicando che la direttrice Jennifer M. Johnson ha ricevuto 76,54 unità di azioni fantasma il 28 giugno 2025 nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le unità, valutate 408,28 $ ciascuna, si convertono in azioni ordinarie con un rapporto di 1 a 1 quando la direttrice lascia il consiglio o in caso di cambio di controllo. Dopo l'accredito, Johnson detiene 474,05 unità equivalenti ad azioni, tutte registrate come proprietà diretta.

La transazione rappresenta un differimento ordinario delle commissioni trimestrali del consiglio, piuttosto che un acquisto o una vendita sul mercato aperto. Con un valore di mercato stimato di circa 31 mila $, la comunicazione è finanziariamente irrilevante rispetto alla capitalizzazione di mercato multimiliardaria di Thermo Fisher. Non sono state esercitate opzioni, non sono state vendute azioni ordinarie e il numero di azioni e la posizione di cassa della società rimangono invariati. Tuttavia, la comunicazione rafforza l'allineamento degli incentivi legando una parte della retribuzione di Johnson ai futuri rendimenti per gli azionisti.

Thermo Fisher Scientific Inc. (TMO) presentó un Formulario 4 el 1 de julio de 2025, revelando que la directora Jennifer M. Johnson recibió 76,54 unidades ficticias de acciones el 28 de junio de 2025 bajo el Plan de Compensación Diferida para Directores de la compañía. Las unidades, valoradas en $408,28 cada una, se convierten en acciones ordinarias en una proporción de 1 a 1 cuando la directora deja la junta o en caso de un cambio de control. Tras el crédito, Johnson posee 474,05 unidades equivalentes a acciones, todas registradas como propiedad directa.

La transacción representa un diferimiento rutinario de las tarifas trimestrales de retención del consejo, en lugar de una compra o venta en el mercado abierto. Con un valor de mercado estimado de aproximadamente $31 mil, la presentación es financieramente insignificante en relación con la capitalización de mercado multimillonaria de Thermo Fisher. No se ejercieron opciones, no se vendieron acciones ordinarias y el recuento de acciones y la posición de efectivo de la empresa permanecen sin cambios. No obstante, la presentación refuerza la alineación de incentivos al vincular una parte de la compensación de Johnson con los futuros rendimientos para los accionistas.

Thermo Fisher Scientific Inc. (TMO)� 2025� 7� 1� Form 4� 제출하여 이사 Jennifer M. Johnson� 2025� 6� 28� 회사� 이사 연기 보상 계획� 따라 76.54 팬텀 스톡 유닛� 부여받았음� 공개했습니다. � 유닛은 $408.28� 가치가 있으�, 이사가 이사회에� 물러나거� 지배권 변� � 1대1 비율� 보통주로 전환됩니�. 해당 부� � Johnson은 � 474.05 주식 등가 유닛� 보유하고 있으�, 모두 직접 소유� 기록되어 있습니다.

이번 거래� 공개 시장에서� 매매가 아닌 분기� 이사� 보수� 일상적인 이연� 나타냅니�. � $31,000� 추정 시장 가치를 가� � 신고� Thermo Fisher� 수십� 달러 규모 시가총액� 비해 재무적으� 미미� 수준입니�. 옵션 행사� 보통� 매각은 없었으며, 회사� 주식 수와 현금 보유액도 변동이 없습니다. 그럼에도 불구하고 이번 신고� Johnson� 보상� 일부� 미래 주주 수익� 연계하여 인센티브 정렬� 강화합니�.

Thermo Fisher Scientific Inc. (TMO) a déposé un formulaire 4 le 1er juillet 2025, révélant que la directrice Jennifer M. Johnson a été créditée de 76,54 unités d'actions fictives le 28 juin 2025 dans le cadre du Plan de Rémunération Différée pour les Administrateurs de la société. Ces unités, évaluées à 408,28 $ chacune, se convertissent en actions ordinaires à raison de 1 pour 1 lorsque la directrice quitte le conseil d'administration ou en cas de changement de contrôle. Après ce crédit, Johnson détient 474,05 unités équivalentes en actions, toutes enregistrées en propriété directe.

Cette opération représente un report habituel des honoraires trimestriels du conseil d'administration, plutôt qu'un achat ou une vente sur le marché ouvert. Avec une valeur marchande estimée à environ 31 000 $, cette déclaration est financièrement insignifiante par rapport à la capitalisation boursière de plusieurs milliards de dollars de Thermo Fisher. Aucune option n'a été exercée, aucune action ordinaire vendue, et le nombre d'actions ainsi que la trésorerie de la société restent inchangés. Néanmoins, cette déclaration renforce l'alignement des incitations en liant une partie de la rémunération de Johnson aux futurs rendements pour les actionnaires.

Thermo Fisher Scientific Inc. (TMO) reichte am 1. Juli 2025 ein Formular 4 ein und gab bekannt, dass die Direktorin Jennifer M. Johnson am 28. Juni 2025 im Rahmen des Deferred Compensation Plans für Direktoren mit 76,54 Phantom-Aktieneinheiten gutgeschrieben wurde. Die Einheiten, die jeweils mit 408,28 $ bewertet sind, werden im Verhältnis 1:1 in Stammaktien umgewandelt, wenn die Direktorin den Vorstand verlässt oder es zu einem Kontrollwechsel kommt. Nach der Gutschrift hält Johnson 474,05 aktienäquivalente Einheiten, die alle als Direktbesitz verbucht sind.

Die Transaktion stellt eine routinemäßige Aufschiebung der vierteljährlichen Vorstandsvergütung dar und ist kein Kauf oder Verkauf am offenen Markt. Mit einem geschätzten Marktwert von etwa 31.000 $ ist die Meldung finanziell unbedeutend im Vergleich zur milliardenschweren Marktkapitalisierung von Thermo Fisher. Es wurden keine Optionen ausgeübt, keine Stammaktien verkauft, und die Aktienanzahl sowie die Barposition des Unternehmens bleiben unverändert. Dennoch stärkt die Meldung die Anreizkompatibilität, indem ein Teil von Johnsons Vergütung an zukünftige Aktionärsrenditen gekoppelt wird.

Free Writing Prospectus to Preliminary Pricing Supplement No. 9,186

Registration Statement Nos. 333-275587; 333-275587-01

Dated July 1, 2025; Filed pursuant to Rule 433

Morgan Stanley

SPXF40D4 Contingent Income Auto-Callable Securities due August 1, 2030

This document provides a summary of the terms of the securities. Investors must carefully review the accompanying preliminary pricing supplement referenced below, product supplement, index supplement and prospectus, and the “Risk Considerations” on the following page, prior to making an investment decision.

Terms

Issuer:

Morgan Stanley Finance LLC

Guarantor:

Morgan Stanley

Underlier:

S&P® 500 Futures 40% Intraday 4% Decrement VT Index (SPXF40D4)

Automatic early redemption:

If, on any redemption determination date, the closing level of the underlier is greater than or equal to the call threshold level, the securities will be automatically redeemed. No further payments will be made on the securities once they have been automatically redeemed.

Call threshold level:

100% of the initial level

Redemption determination dates:

Beginning after 6 months, monthly

Contingent coupon:

14.50% to 15.50% per annum

Coupon payment dates:

Monthly

Coupon barrier level:

70% of the initial level

Downside threshold level:

60% of the initial level

Pricing date:

July 28, 2025

Final observation date:

July 29, 2030

Maturity date:

August 1, 2030

CUSIP:

61778NGE5

Estimated value:

$899.70 per security, or within $49.70 of that estimate

Preliminary pricing supplement:

https://www.sec.gov/Archives/edgar/data/895421/000183988225036029/ms9186_424b2-19686.htm

1All payments are subject to our credit risk

 

Hypothetical Payment at Maturity1

(if the securities have not been automatically redeemed)

% Change in Closing Level of the Underlier

Payment at Maturity per Security (excluding any contingent coupon payable at maturity)

+100.00%

$1,000.00

+80.00%

$1,000.00

+60.00%

$1,000.00

+40.00%

$1,000.00

+20.00%

$1,000.00

0.00%

$1,000.00

-20.00%

$1,000.00

-40.00%

$1,000.00

-41.00%

$590.00

-60.00%

$400.00

-80.00%

$200.00

-100.00%

$0.00


 

 

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free 1-800-584-6837.

Underlier(s)

For more information about the underlier(s), including historical performance information, see the accompanying preliminary pricing supplement.

Risk Considerations

The risks set forth below are discussed in more detail in the “Risk Factors” section in the accompanying preliminary pricing supplement. Please review those risk factors carefully prior to making an investment decision.

Risks Relating to an Investment in the Securities

The securities do not guarantee the return of any principal.

The securities do not provide for the regular payment of interest.

Payment of the contingent coupon is based on the closing level of the underlier on only the related observation date at the end of the related interest period.

Investors will not participate in any appreciation in the value of the underlier.

The securities are subject to early redemption risk.

The market price of the securities may be influenced by many unpredictable factors.

The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads may adversely affect the market value of the securities.

As a finance subsidiary, MSFL has no independent operations and will have no independent assets.

The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities, cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market prices.

The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from those of other dealers and is not a maximum or minimum secondary market price.

The securities will not be listed on any securities exchange and secondary trading may be limited.

As discussed in more detail in the accompanying product supplement, investing in the securities is not equivalent to investing in the underlier(s).

The U.S. federal income tax consequences of an investment in the securities are uncertain.

Risks Relating to the Underlier(s)

No assurance can be given that the investment strategy used to construct the underlier will achieve its intended results or that the underlier will be successful or will outperform any alternative index or strategy that might reference the futures contract.

The decrement of 4% per annum will adversely affect the performance of the underlier in all cases, whether the underlier appreciates or depreciates. The underlier includes a decrement feature, whereby 4% per annum is deducted daily from the level of the underlier.

The underlier is subject to risks associated with the use of significant leverage.

The underlier may not be fully invested.

The underlier was established on August 30, 2024 and therefore has very limited operating history.

As the underlier is new and has very limited historical performance, any investment in the underlier may involve greater risk than an investment in an index with longer actual historical performance and a proven track record.

Adjustments to the S&P® 500 Futures 40% Intraday 4% Decrement VT Index could adversely affect the value of the securities.

Because your return on the securities will depend upon the performance of the underlier(s), the securities are subject to the following risk(s), as discussed in more detail in the accompanying product supplement.

oHigher future prices of a futures contract to which the underlier is linked relative to its current prices may adversely affect the value of the underlier and the value of the securities.

oSuspensions or disruptions of market trading in futures markets could adversely affect the value of the securities.

oLegal and regulatory changes could adversely affect the return on and value of the securities.

Risks Relating to Conflicts of Interest

The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect to the securities.

Hedging and trading activity by our affiliates could potentially adversely affect the value of the securities.

Tax Considerations

You should review carefully the discussion in the accompanying preliminary pricing supplement under the caption “Additional Information About the Securities–United States federal income tax considerations” concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser.

 

FAQ

How many Thermo Fisher (TMO) shares did Jennifer M. Johnson acquire?

She was credited with 76.54 phantom stock units, convertible 1-for-1 into common shares.

What price was used to credit the phantom stock units?

Units were valued at $408.28 each, based on the quarter-end closing price.

What is Johnson’s total TMO beneficial ownership after the transaction?

Her deferred account now holds 474.05 common-stock equivalent units.

Is this an open-market purchase of Thermo Fisher shares?

No. The units were issued through the Deferred Compensation Plan for Directors, not bought on the open market.

When can the phantom stock units be converted to common stock?

They convert upon cessation of director service or a change of control of the company.
Morgan Stanley

NYSE:MS

MS Rankings

MS Latest News

MS Latest SEC Filings

MS Stock Data

224.20B
1.22B
23.64%
62.12%
0.89%
Capital Markets
Security Brokers, Dealers & Flotation Companies
United States
NEW YORK